ACE-031 dosage: reported doses and schedule

An experimental muscle-growth protein whose Duchenne program stopped over bleeding concerns.

Also called: Ramatercept, ACE031, ActRIIB-IgG1, ActRIIB-Fc.

Myostatin pathway · Soluble activin receptor IIB–IgG1 Fc fusion protein.

Typical reported dose: 100 mcg in each shoulder, one time

  • Single-dose lower boundary: 0.02 mg/kg once once, under the skin. Studied in a trial. Studied in: Healthy postmenopausal women aged 45–75. (source)
  • Single-dose 1 mg/kg cohort: 1 mg/kg once once, under the skin. Studied in a trial. Studied in: Healthy postmenopausal women aged 45–75. (source)
  • Single-dose 3 mg/kg cohort: 3 mg/kg once once, under the skin. Studied in a trial. Studied in: Healthy postmenopausal women aged 45–75. (source)
  • Duchenne 0.5 mg/kg: 0.5 mg/kg every four weeks every four weeks, under the skin. Studied in a trial. Studied in: Boys with Duchenne muscular dystrophy on stable steroids. (source)
  • Duchenne 1 mg/kg: 1 mg/kg every two weeks every two weeks, under the skin. Studied in a trial. Studied in: Boys with Duchenne muscular dystrophy on stable steroids. (source)
  • Reported shoulder test injections: 100 mcg in each shoulder; 200 mcg total one reported test session, into muscle. Reported by users, rare report. Studied in: Adults discussing self-use for muscle growth. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Related to ACE-031

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.